Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

Core Viewpoint - Altamira Therapeutics Ltd. will be delisted from Nasdaq due to non-compliance with minimum bid price requirements and will transition to trading on the OTCQB marketplace under the ticker symbol "CYTOF" [1][4]. Group 1: Company Transition - The Nasdaq Hearings Panel determined to delist the Company's common shares due to failure to comply with Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share [1]. - The transition to OTCQB is seen as an opportunity for the Company to focus on growth without the pressure of the minimum bid price rule, eliminating the need for a reverse stock split [2][4]. - The common shares will begin trading on OTCQB on December 20, 2024, ensuring uninterrupted market activity for shareholders [4]. Group 2: Company Operations and Products - Altamira Therapeutics is developing RNA delivery technologies, specifically peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues [2]. - The Company has two flagship siRNA programs in preclinical development: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis [2]. - Altamira holds a 49% stake in Altamira Medica AG, which has a commercial-stage asset, Bentrio®, an OTC nasal spray for allergic rhinitis [2].